Rationale: We previously discovered the human 10T3 C (Trp4Arg) missense mutation in exon 2 of the muscle LIM protein (MLP, CSRP3) gene. Objective: We sought to study the effects of this single-nucleotide polymorphism in the in vivo situation. Methods and Results: We now report the generation and detailed analysis of the corresponding Mlp W4R/؉ and Mlp W4R/W4R knock-in animals, which develop an age-and gene dosage-dependent hypertrophic cardiomyopathy and heart failure phenotype, characterized by almost complete loss of contractile reserve under catecholamine induced stress. In addition, evidence for skeletal muscle pathology, which might have implications for human mutation carriers, was observed. Importantly, we found significantly reduced MLP mRNA and MLP protein expression levels in hearts of heterozygous and homozygous W4R-MLP knock-in animals. We also detected a weaker in vitro interaction of telethonin with W4R-MLP than with wild-type MLP. These alterations may contribute to an increased nuclear localization of W4R-MLP, which was observed by immunohistochemistry. Conclusions: Given the well-known high frequency of this mutation in Caucasians of up to 1%, our data suggest that W4R-MLP might contribute significantly to human cardiovascular disease. (Circ Res. 2010;106:695-704.) 
C ardiomyopathies are primary disorders of cardiac muscle and represent major causes of morbidity and mortality at all ages. 1 With a prevalence of 200 per 100 000 individuals, hypertrophic cardiomyopathy (HCM) is the most common cardiovascular disease inherited as an autosomal dominant trait and accounts for Ϸ36% of all sudden deaths in the United States in competitive athletes. Onset of disease is variable and can be late in adolescence. 1 In the majority of cases, the disease is caused by mutations in sarcomeric and/or structural components. 2 However, the underlying molecular mechanisms remain unclear.
We cloned and sequenced previously the human MLP gene (CLP, CRP3, or CSRP3), which is encoded by Ϸ20 000 bp and organized into 6 exons, giving rise to a 194-aa LIM only protein. 3 Homozygous loss of Mlp in a genetically engineered mouse model results in cardiac hypertrophy followed by dilated cardiomyopathy (DCM), 4 the first model for this condition in a genetically manipulatable organism. In addition, we discovered and characterized the 10T3 C (Trp4Arg) missense mutation in exon 2 of the MLP gene, the first human MLP mutation (and together with a telethonin mutation, the first Z-disk mutation in general) linked to cardiomyopathy, and proposed a role for this gene in cardiac mechanosensation. 3 Because of the well-known limitations of human studies, owing in part to differences in environmental and epigenetic factors, it is often impossible to perform an in depth functional analysis of mutations in the human setting. Therefore, we generated Mlp W4R/ϩ and Mlp W4R/W4R knock-in (KI) animals and compared the phenotype with Mlp ϩ/ϩ littermates (Figure 1 ).
Gene Targeting
Gene targeting was performed essentially as described in Arber et al. 4 Echocardiography All animal studies were performed in accordance with institutional, national, and international guidelines and regulations (local ethics committee #33.11.42502-04-075/08). For echocardiography, mice were anesthetized with isoflurane and transthoracic echocardiography was performed by a blinded investigator as described previously. 5
Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry
MLP W4R/W4R (KI) or MLP ϩ/ϩ (wild-type [WT]) left ventricular (LV) tissue (12-month-old mice) was used to perform 2D difference gel electrophoresis (2D-DIGE) 6,7 as described in detail in the Online Data Supplement.
Glutathione S-Transferase Pull-Down Assays and MLP-Green Fluorescent Protein Overexpression in Embryonic Rat Cardiomyocytes
MLP, W4R-MLP, and telethonin (TCap) constructs were recombinantly expressed using pGEX4T2 vector and pull down assays were performed according to standard protocols.
Cardiomyocytes were isolated from embryonic day (E)18 hearts by enzymatic dissociation, plated at a density of 8ϫ10 5 cells/mm 2 , and cultured at 37°C and 5% CO 2 in Iscove's modified Dulbecco's medium supplemented with 20% FCS. 8 Transfections were performed with recombinantly expressed, enhanced green fluorescent protein (GFP)-coupled MLP or W4R-MLP constructs overexpressed in 24-to 48-hour cell cultures using standard lipofection methods (reagent, Escort IV; Sigma).
Statistics
For the comparison of different animal groups during echocardiography, the ANOVA F test, including sex adjustment, was used. For the parameters showing significance in the overall test, a pairwise comparison of the 3 different genotypes was performed by contrasts (closed testing procedure). Because of the high correlation of the different parameters to each other, no multiple testing or correction was used, and probability values of Յ0.05 were considered significant. For analysis of variations in fiber diameter the Wilcoxon signed-rank test for unpaired testing was applied. The Mann-Whitney U test was used for the analysis of hemodynamic parameters (data were not normally distributed), and the Student's t test was applied for analysis of quantitative PCRs.
Results
Mlp W4R/ϩ and Mlp W4R/W4R KI mice are born in the expected mendelian ratios, they are fertile and develop normal until adolescence. However, at an age between approximately 12 and 14 months (approximately half the life span of a mouse), heterozygous, as well as homozygous, KI animals develop severe septal hypertrophy, a hallmark of HCM (Table) . In contrast to the heterozygous animals, which develop a moderate but significant HCM phenotype, homozygous KI animals develop a severe form of HCM (Table) : each parameter indicative of hypertrophy is significantly (PϽ0.05) or highly significantly increased (PϽ0.01) in homozygous KI animals. An important feature of the phenotype is the substantial gain in fractional shortening percentage, another hallmark of HCM, that is observed in all mutation carriers. An increase in fractional shortening percentage indicates, but is not necessarily associated with, a gain of function. 9 We also performed in vivo hemodynamic measurements in this line and found, besides a significant increase in heart weight per body weight (BW), an increased lung weight per BW ratio, which might indicate pulmonary edema as an indirect sign of heart failure. However, we measured normal functional parameters under baseline conditions (nϭ6 for each group, Online Table I ). WT animals responded to hemodynamic stress in form of adrenalin application for 2 and 3 minutes with the expected significant increase in myocardial performance as measured by decreased end-systolic volumes (Figure 2A ), decreased end-diastolic volumes ( Figure 2B ), and increased LV contractility ( Figure 2D ). In contrast, W4R-MLP KI animals were unable to increase myocardial function under these conditions, thereby revealing a heart failure phenotype (Online Table I ).
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This striking observation led us to search for the underlying molecular mechanisms. In heterozygous, as well as homozygous, W4R-MLP KI animals, we found significantly reduced MLP mRNA ( Figure 3A ) and MLP protein expression levels ( Figure 3B ). Differential analysis of protein expression levels in 12-month-old Mlp ϩ/ϩ and Mlp W4R/W4R hearts using 2D difference gel electrophoresis (2D-DIGE) showed upregulation, among others, of myofibrillar proteins (eg, tropomyosin and ␣-actinin), consistent with a hypertrophy phenotype (Online Figures I and II; Online Table II) . , ejection fraction (EF) (C), and peak rate of LV pressure rise normalized for end-diastolic volume (dP/dtmax/Ved), as a marker for LV contractility (D), under basal as well as under stressed conditions (2 and 3 minutes after adrenalin injection). Under basal conditions, W4R-MLP KI animals showed a tendency for higher end-diastolic volumes (Pϭ0.065) but no difference in ejection fraction, LV end-systolic volume, or LV contractility. However, KI animals developed severe heart failure under stressed conditions (as measured by end-systolic volumes, ejection fraction, and contractility), thus uncovering a cardiomyopathy phenotype. KI indicates homozygous W4R-MLP KI animals. *PϽ0.05 vs basal hemodynamic status of the same genotype; #PϽ0.05 vs WT animals under same stress conditions; §PϽ0.05 vs hemodynamic status 2 minutes after adrenaline injection of the same genotype (nϭ6 per group).
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When we analyzed gene expression patterns, we found no change in brain natriuretic peptide (BNP) and atrial natriuretic factor mRNA expression levels but slightly increased ␤ myosin heavy chain protein expression levels in the W4R-MLP KI animals, indicating the presence of a hypertrophic gene program (Online Figure I) . We also applied 10% biaxial stretch at 0.5 Hz to cultured cardiomyocytes, isolated from 8-to 12-week-old W4R-MLP KI hearts, as well as WT littermate controls, and analyzed BNP mRNA expression. Interestingly, similar to the situation in MLP-deficient cardiomyocytes, 3 there was a clear trend suggesting the stretch-induced upregulation of BNP in cultured WT myocytes did not take place in W4R-MLP KI cardiomyocytes (Online Figure V) .
MLP is known to interact with calcineurin, 10 and increased calcineurin expression and/or activity levels are well known causes of myocardial hypertrophy. 11 Therefore, we measured MCIP1 mRNA (modulatory calcineurin interacting protein, regulator of calcineurin 1), which has been used as an indicator of calcineurin activity previously 12, 13 but did not find any significant changes in the expression of this protein (Online Figure VI) .
Moreover, in-depth analyses of the ultrastructure of KI hearts revealed myocardial disarray at the cellular, as well as subcellular, level (Figure 4A through 4G; Online Figure VII ). Mutant animals also revealed significant fibrosis as detected by increased collagen 1 in the extracellular matrix ( Figure  4H ). Interestingly, in comparison to WT littermate control hearts, MLP in the KI animals was found to be less abundant at the sarcomeric Z-disk, whereas MLP in the nucleus was elevated (Figure 5A through 5E; Online Figure VIII) .
Several lines of evidence indicate a critical role for MLP also in skeletal muscle. 14 Histological analysis of the quadriceps femoris muscle of 1-year-old Mlp W4R/W4R KI animals revealed normal fiber-type distribution and no increase in the proportion of centrally located nuclei but demonstrated mild myopathic features with a significantly increased variation in fiber diameter compared to controls (PϽ0.03) ( Figure 6A and 6B). Measurements of passive elastic properties of fast muscle fibers from chemically permeabilized musculus vastus lateralis of WT and Mlp W4R/W4R KI mice under relaxing conditions revealed a substantial decrease in fiber stiffness at low and high ionic strength in the homozygous KI mice ( Figure 6C ). Stiffness measurements under these conditions, performed with different speeds of stretch at low and high ionic strength, allowed the differentiation of contributions from passive elastic components and/or weak acto-myosin interactions. 15 Therefore, the larger compliance found in Mlp W4R/W4R muscle fibers is most likely attributable to changes in both passive structural components of the fibers and weak acto-myosin interactions. Confocal microscopy of skinned musculus vastus lateralis fibers immunofluorescently labeled with MLPspecific antibodies ( Figure 6D and Online Figure IX) revealed specific staining at the Z-disk and M-band; the latter structure, however, was much more faintly stained. The observed changes in skeletal muscle compliance were not attributable to changes in titin isoform expression patterns, because we did not find any alterations in N2A-titin isoform size by 2% SDS-PAGE in W4R-MLP KI soleus skeletal muscle compared to WT muscle (Online Figure X) .
In addition, the W4R-MLP mutation caused a significant decrease in the in vitro affinity of MLP to telethonin (TCap), a known MLP-interacting protein located at the periphery of the Z-disk ( Figure 7A ). However, W4R-MLP still localized to the Z-disk when the mutation was introduced into a MLP-GFP construct and overexpressed in late-embryonic rat cardiomyocyte cultures ( Figure 7B and 7C ). We note that WT and mutant MLP are not restricted to a Z-disk location but are found in the nucleus, the cytoplasm, and at gap junctions, as well. 16, 17 
Discussion
Here, we report the generation and detailed analysis of Mlp W4R/ϩ and Mlp W4R/W4R KI mice, which develop an age-and gene dosage-dependent hypertrophic cardiomyopathy and heart failure phenotype. In addition, we provide evidence for the presence of skeletal muscle pathology in these animals, a fact that might have implications for human W4R-MLP mutation carriers in which, to the best of our knowledge, no skeletal muscle alteration has been described to date.
According to echocardiography measurements, W4R-MLP heterozygous, as well as homozygous, KI animals developed signs of hypertrophic cardiomyopathy, including increases in septum wall thickness, fractional shortening, and wall thickness per diameter (h/r). In addition, homozygous KI animals showed increased LV mass per BW and, interestingly, significantly reduced body weight. We do not have an explanation for the significantly decreased body weight in the homozygous KI group, but it is possible that the observed skeletal myopathic effects play a role. The increase in fractional shortening under baseline conditions in the genetically altered animals, although interesting, is unlikely to be attributable to enhanced myocardial function; rather, it may be explained by the smaller LV end-systolic and end-diastolic diameters found in these animals. 9 Data obtained from animals undergoing hemodynamic analysis (Online Table I ) support the findings obtained by echocardiography. Interestingly, the hemodynamic parameters under baseline conditions were normal (Online Table I ). However, slightly but significantly increased lung weight per BW ratios might indicate the presence of pulmonary edema in the KI animals, an indirect sign of heart failure.
Importantly, hemodynamic stress in form of adrenalin application for 2 and 3 minutes revealed a blunted response in the KI animals, as judged by a lack of significant 
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changes in end-systolic volumes (Figure 2A) , end-diastolic volumes ( Figure 2B ), and LV contractility ( Figure 2D ). This finding is remarkable and suggests that the ventricular performance is maintained at the expense of limited myocardial contractile reserve, and that inotropic stimulation unmasks the heart failure phenotype present in these animals. In this context, we point out that two individuals previously identified as W4R-MLP mutation carriers 3 developed heart failure after performing extreme sports (ie, marathon running and free climbing).
Although heterozygous MLP knock out animals, which express significantly less MLP protein than WT littermates, 4 do not develop any spontaneous phenotype, heart failure can easily be induced in these animals by additional stressing, such as ischemia. 10 Similarly, the significantly reduced MLP mRNA and protein expression levels observed in heterozygous and homozygous W4R-MLP KI animals ( Figure 3A and 3B and Figure 7D ) might ultimately lead to hypertrophy and heart failure.
Another potentially disease causing alteration is the reduced protein-protein interaction between the Z-disk protein telethonin and W4R-MLP compared to WT-MLP. Although we found that overexpressed W4R-MLP coupled to green fluorescent protein still bound to Z-disks in cultured cardiomyocytes, a reduced binding to telethonin might ultimately contribute to loss of MLP at the sarcomeric Z-disk and facilitate the observed translocation of W4R-MLP into the nucleus ( Figure 5A through 5E and Figure 7D ). In this context, we note that MLP translocates to the nucleus via its nuclear localization sequence located within the first glycine-rich domain; nuclear MLP is essential for proper sarcomeric organization. 18 The func-tion of MLP in the nucleus is poorly understood. However, this protein, which is unable to bind to DNA directly, can act as a cofactor of transcription by interacting with a variety of different transcription factors, such as MyoD, myogenin, and MRF. 19 Therefore, increased W4R-MLP in the nucleus could readily affect transcription and may be one reason why W4R-MLP KI animals show blunted BNP gene expression (Online Figure V) .
MLP was found to localize to the sarcomeric Z-disk in skeletal and cardiac muscle tissue, confirming results of several previous MLP localization studies in striated muscle. 4,10,20 -22 Notably, we used different anti-MLP antibodies, including a monoclonal described in a recent report, 23 as well as one developed by Hoshijima and colleagues 3 and another by Caroni and colleagues. 24 Besides a Z-disk MLP localization in skeletal muscle tissue, we observed faint staining of MLP at the M lines (close to titin kinase domain of titin 25 ), the significance of which needs to be determined.
W4R-MLP KI skeletal muscles were significantly more compliant in comparison to WT littermate controls. This finding is consistent with the increased compliance of MLP deficient mouse heart samples reported earlier. 3 The molecular mechanisms leading to reduced skeletal muscle passive stiffness remains to be determined, but we showed they do not include changes in titin isoform size. Whether posttranslational modifications of the elastic titin region (eg, phosphorylation or disulphide bridge formation) are involved in altering fiber stiffness 26 is an issue worth studying in the future. Alternatively, the decrease in Mlp W4R/W4R fiber stiffness could be attributable to a direct structural role of MLP in the Z-disk and/or secondary effects via involve- ment of MLP in signaling cascades that regulate myocyte remodeling. 3, 18 In any case, our finding that the W4R-MLP mutation affects the skeletal muscle confirms a previously reported role for MLP in skeletal muscle maintenance and regeneration, 14 as well as a report on skeletal muscle pathology in patients carrying a MLP mutation. 23 Our results might have implications for human 10T3 C (Trp4Arg) MLP carriers, which may show signs of both heart and skeletal muscle pathologies.
In W4R-MLP KI hearts, hemodynamic measurements showed no significant change in relaxation constant, Tau (Online Table I ). Possibly, an increased compliance of the cardiomyocytes in W4R-MLP hearts had been cancelled out by the increased collagen I expression causing increased collagen-based stiffness.
Since our initial description of the 10T3 C (Trp4Arg) MLP missense mutation, 3 this mutation has been found in additional individuals affected by either DCM 27 or HCM. 23, 28, 29 Possibly, the individuals first described by us 3 and others 27 to have the 10T3 C (Trp4Arg) MLP missense mutation had been at later stages of the disease, when the mutation is DCM-associated. However, at earlier stages, the mutation seems to be associated with HCM. 23, 28, 29 In addition, confounding effects of incomplete penetrance, genetic modifiers, or different envi- Figure 6 . A and B, W4R-MLP KI animals are characterized by myopathic changes in skeletal muscle. A, In comparison to controls (CON), hematoxylin/eosin staining of transverse muscle sections (quadriceps femoris muscle) reveals an increased variation in fiber diameter in mutant animals. Scale barϭ50 m. B, Distribution of fiber diameters. Averages were formed from all individual means and from all individual variances for the animals of 1 group, yielding 2 different average Gaussian distribution curves. Interestingly, W4R-MLP KI animals display significantly larger variation in their myofiber diameters than WT animals (nϭ5 muscles from 12-month-old animals, with a total of 700 to 800 myofibers; PϽ0.03). C, Stiffness (passive elastic properties) of relaxed fibers isolated from chemically permeabilized musculus vastus lateralis of Mlp W4R/W4R KI mice (open symbols) is significantly lower than in fibers from control mice (WT) (filled symbols). On average, stiffness recorded at different speeds of stretch at ionic strength 50 mmol/L (squares) and 220 mmol/L (circles) was reduced by 45% and 58%, respectively (nϭ5 to 9 fibers from 2 KI mice and 3 WT mice; error bars sometimes smaller than symbol). D, Longitudinal optical section of a single fiber derived from musculus vastus lateralis of a Mlp W4R/W4R KI obtained by confocal microscopy shows colocalization (overlay, right image) of ␣-actinin (TRITC fluorescence, middle image; fiber not yet equilibrated with antibodies throughout cross-section) and MLP (FITC fluorescence, left image; antibody from P. Caroni 4 ) in the Z-disk (sarcomere length, 2.5 m). Faint MLP labeling is also observed in the M-line of the sarcomeres.
ronmental circumstances might be at play. Moreover, HCM and DCM phenotypes do not exclude one another and are sometimes difficult to distinguish (ie, "burnt out" phase HCM). This notion is supported by the spontaneous development of an HCM phenotype in the 10T3 C (Trp4Arg) MLP KI animals and by the fact that at least 10% to 20% of all HCM patients develop a DCM phenotype later in life 30 (reviewed elsewhere 31 ). An alternative possibility is that this mutation is capable of causing either an HCM or a DCM phenotype, depending on modifier genes and/or epigenetic factors. This possibility is confirmed by the Syrian hamster model, where the same ␦-sarcoglycan mutation causes, in 2 different lines, either an HCM (BIO 14.6) or a DCM (TO-2) phenotype. 32, 33 Heterozygous, as well as homozygous, W4R-MLP KI animals develop the phenotype relatively late at an age of Ϸ12 months. A late-onset phenotype, which has also been observed for myosin binding protein C mutations, 34 might explain the presence of several healthy mutation carriers in younger human individuals and the fact that the fraction of healthy 10T3 C (Trp4Arg) MLP carriers drops in an older population. 23 Similarly, late onset of disease might be a reason for the presence of this mutation in another control population, where the cardiovascular phenotype was not determined. 29 In summary, our data support the notion that the 10T3 C (Trp4Arg) MLP missense mutation is a late-onset and gene dosage-dependent, disease-causing mutation.
Given the well-known association of cardiac hypertrophy with cardiovascular morbidity and mortality (reviewed by Hill and Olson 35 ), it is clear that the 10T3 C (Trp4Arg) MLP missense mutation conveys a significant risk for human individuals affected by this mutation (Figure 7D ). To the best of our knowledge, the 10T3 C (Trp4Arg) MLP is the most frequent cardiovascular disease gene in European whites, comparable to a recently published myosin binding protein C variant common among Southern Asians. 36, 37 We speculate that the W4R-MLP mutation, because of its high frequency of up to 1%, may convey (partial) myocardial protection or at least offer an advantage under certain conditions (otherwise, evolution might not have allowed its widespread distribution) but, in the end, may exert detrimental effects. Gene dosage effects are well known to modify the progression of diseases like HCM and DCM considerably, both in human individuals 38 and in animal models. 39 In this context, our Mlp W4R/ϩ and Mlp W4R/W4R KI animals may represent a novel "humanized" mouse model to recapitulate and study major features of cardiomyopathies. Future research should focus on elucidating the underlying age-and gene dosage-dependent effects. Moreover, innovative therapeutic strategies have to be developed to reverse the detrimental effects seen in HCM and DCM patients. Our novel model of Mlp W4R/W4R mice could help facilitate progress in this field. 
